Salem Partners, LLC - Investment Banking and Wealth Management
  • Home
  • About
  • Investment Banking
    • Valuation Services
    • Media & Entertainment
    • Healthcare & Life Sciences
    • Industrials
    • Real Estate
    • Specialty & Lender Finance
    • Transactions
  • Wealth Management
    • Portfolio Log In
  • Real Estate Development
  • Professionals
  • News
  • Contact

OncoNano Announces Positive Preclinical Data for ONM-501 at AACR 2022 Annual Meeting

4/13/2022

 
Picture
OncoNano Medicine, Inc. today announced positive results from a preclinical study of ONM-501, a novel dual-activating polyvalent STING (STimulator of INterferon Genes) agonist for immuno-oncology applications. The data, presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, demonstrate the efficacy and tolerability of ONM-501 in animal models for multiple tumor types. ONM-501 is formulated with the core OncoNano OMNITM polymer technology consisting of STING-activating pH-sensitive micelles loaded with an endogenous agonist...(read more). 

OncoNano Announces Positive Preclinical Data for Tumor Specific Delivery with the ON-BOARD Platform at AACR 2022 Annual Meeting

4/12/2022

 
Picture
OncoNano Medicine, Inc. today announced positive results from the company’s ON-BOARD™ pH-sensitive nanoparticle platform. The data, presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, demonstrate that the clinically validated ON-BOARD™ platform has the potential to be a universal tool for tumor-specific activation and the efficient delivery of proteins for an improved therapeutic index.

“Our ON-BOARD micelle platform is designed to efficiently carry a broad range of payloads to the tumor microenvironment. Capable of being tuned to deliver either small molecules or biologics, the ON-BOARD platform has the potential to be a universal tool for targeted delivery of therapeutics to a range of cancers,” said Tian Zhao, Ph.D., Vice President of Research & Development for OncoNano Medicine, Inc...(read more). 

OncoNano Announces Results from a Phase 2 Study and Presents at the 2021 World Molecular Imaging Congress (WMIC)

10/14/2021

 
Picture
OncoNano Medicine, Inc. announced results from a Phase 2 study of its lead clinical development candidate, pegsitacianine, presented as a late-breaking oral presentation at the 2021 World Molecular Imaging Congress (WMIC). This late-breaking oral presentation by Dr. Jason Newman of the University of Pennsylvania Health System revealed the fluorescent nanoprobe, pegsitacianine, provided real-time surgical imaging in a tumor-agnostic manner for the accurate identification of malignant tissue in the operating room.

Pegsitacianine is an intraoperative fluorescence imaging agent under development by OncoNano Medicine for the detection of cancerous tissue in patients undergoing removal of their solid tumor. Relying on an ultra pH-sensitive activation mechanism of OncoNano’s ON-BOARD
TM platform, pegsitacianine exists in a fluorescently dark (“Off”) state at physiological pH but transitions rapidly to a fluorescently “On” state in the presence of the elevated acidic tumor microenvironment...(read more)

OncoNano Medicine Announces Positive Preclinical Data at AACR Virtual Conference on Tumor Immunology and Immunotherapy

10/8/2021

 
Picture
OncoNano Medicine, Inc. announced positive results from its preclinical study of ONM-501, a novel dual-activating polyvalent STING agonist for immuno-oncology applications. The data, presented at The American Association for Cancer Research (AACR) Virtual Conference on Tumor Immunology and Immunotherapy, demonstrate strong efficacy in multiple tumor models.

“We are excited by the positive preclinical results for ONM-501 recently presented at AACR. STING plays a crucial role in mediating our innate immune systems but has consistently been a challenging pathway to target,” said Martin Driscoll, Chief Executive Officer of OncoNano Medicine, Inc...(read more)


OncoNano Medicine to Present at the American Association for Cancer Research Virtual Conference on Tumor Immunology and Immunotherapy

9/30/2021

 
Picture
​OncoNano Medicine, Inc. today announced a poster presentation at The American Association for Cancer Research (AACR) Virtual Conference on Tumor Immunology and Immunotherapy to be held on October 5-6, 2021. 

The development of ONM-501 represents a new concept in STING activation that could overcome the challenges observed with earlier STING agonists. ONM-501 encapsulates the endogenous STING agonist cGAMP with a proprietary micelle that induces polyvalent STING condensation and prolongs innate immune activation to offer dual ‘burst’ and ‘sustained’ STING activation for a potential highly effective immunotherapy against cancer...(read more)
​

Onconano Announces Expanded Research Collaboration with UT SouthWestern Medical Center to Advance Development of New Cancer Therapies

9/22/2021

 
Picture
OncoNano Medicine, Inc., a clinical-stage company utilizing the principles of molecular cooperativity in drug design to exploit universal tumor and immune targets to diagnose and treat cancer, today announced a multi-year collaboration with The University of Texas Southwestern Medical Center (UTSW) to discover and conduct translational research of novel cancer therapeutics that leverage OncoNano’s core nanotechnology platform. OncoNano will sponsor research efforts in the laboratory of Professor Jinming Gao of UTSW with the objective of uncovering new cancer therapies that can benefit from OncoNano’s ultra pH-sensitive polymeric micelles. OncoNano will have an exclusive option to license new technology arising from the research conducted under this agreement. 

“
We are excited to expand our research collaboration with the UT Southwestern Medical Center and the prominent UTSW laboratory led by Dr. Jinming Gao,” said Martin Driscoll, Chief Executive Officer of OncoNano Medicine, Inc...(read more)

Onconano Medicine to Present at the World Molecular Imaging Congress

9/20/2021

 
Picture
OncoNano Medicine, Inc. today announced an oral presentation at The World Molecular Imaging Congress 2021 (WMIC) to be held virtually on October 6-9, 2021.

​
OncoNano Medicine is developing a new class of products that utilize principles of molecular cooperativity in their design to exploit pH as a biomarker to diagnose and treat cancer with high specificity. Our product candidates and interventions are designed to help patients across the continuum of cancer care and include solid tumor therapeutics, agents for real-time image-guided surgery and a platform of immune-oncology therapeutics that activate and guide the body’s immune system to target cancer...(read more)


Onconano Medicine Lands $50m in Series B to Spur Nanosensor that 'Lights Up' Cancer

6/22/2021

 
Picture
Onconano Medicine Inc. raised around $50 million in series B financing to accelerate the momentum of its technology designed to diagnose and treat cancer with high specificity. The biotech company’s nanosensor works by reacting to low pH and illuminates cancer like a lightbulb, distinguishing cancerous tissue from healthy tissue. This is intended to make it easier for surgeons to remove cancer cells while leaving healthy, functional tissue intact.

The company’s product candidates exploit pH as a biomarker to help patients across the continuum of cancer care, from diagnosis to treatment, and have been gaining momentum in recent years. They include solid tumor therapeutics, agents for real-time image-guided surgery, as well as a platform of product candidates that activate and guide the immune system to target cancer...(read more)

OncoNano Medicine Raises ~$50 Million in Series B Financing

6/17/2021

 
Picture
OncoNano Medicine, Inc. today announced the raise of an approximate $50 million Series B financing led by the healthcare investment team at Advantech Capital, a China-based cross-border institutional investment fund. Proceeds of the financing will be used, in part, to support the Phase 3 clinical trials in the U.S. and Europe for pegsitacianine, an innovative real-time imaging agent used in intraoperative surgical resection of solid tumors, and accelerate the advancement of the company’s first therapeutic development program, ONM-501, a novel immune-therapeutic formulated with the company’s core delivery technology...(read more)

Femasys Inc. Announces Pricing of Initial Public Offering

6/17/2021

 
Picture
Femasys Inc., a biomedical company focused on transforming women's healthcare by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas, today announced the pricing of its initial public offering of 2,650,000 shares of its common stock at a public price of $13.00 per share. The gross proceeds to Femasys from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $34.45 million. All of the shares are being offered by Femasys. In addition, Femasys has granted the underwriters a 30-day option to purchase an additional 397,500 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions.

The shares are expected to begin trading on the Nasdaq Capital Market on June 18, 2021, under the ticker symbol “FEMY.” The offering is expected to close on June 22, 2021, subject to customary closing conditions...(read more)

OncoNano Announces Presentations at the 2019 SITC Annual Meeting

11/5/2019

 
Picture
 OncoNano Medicine, Inc., a biotechnology company developing ultra pH-sensitive micelles for the detection, staging and treatment of cancer, today announced two poster presentations – including a late-breaking abstract – for the Society for the Immunotherapy of Cancer (SITC) Annual Meeting to be held in National Harbor, Maryland, November 6-10. OncoNano’s core technology is a library of tunable, ultra pH-sensitive micelles that exist intact under baseline physiological pH conditions but dissociate to release their payload under different, predesignated pH levels... (read more)


OncoNano Awarded $15.4 Million Grant from Cancer Prevention and Research Institute of Texas

8/27/2019

 
Picture
OncoNano Medicine, Inc. today announced that it has been awarded $15.4 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to advance ONM-500, one of OncoNano’s innovative oncology product candidates. In ONM-500, OncoNano leverages its proprietary pH-sensitive micelle technology to deliver antigens while activating innate immunity for the treatment of cancers caused by the human papilloma virus (HPV). This grant award adds to an initial $6 million grant that the company received from CPRIT in 2014 for advancement of the company’s ONM-100, where OncoNano’s micelle technology is being used to intraoperatively image tumors during surgical resection, currently in Phase 2 clinical trials... (read more)

OncoNano Announces Completion of Phase 1a Study and Expands into Phase 1b for Intraoperative Imaging Agent to Detect Tumors and Metastatic Lymph Nodes That Often Go Undetected During Surgery

12/5/2018

 
Picture
OncoNano Medicine, Inc. today announced the completion of its Phase 1a clinical trial and expansion into Phase 1b to evaluate ONM-100, the intravenously administered imaging agent to detect tumors and metastatic lymph nodes in solid cancers during surgery. The results of Phase 1a will be included in a poster presentation at the San Antonio Breast Cancer Symposium being held on December 4-8, 2018... (read more)

AsclepiX Therapeutics Raises $5M in New Funding

11/13/2018

 
Picture
​AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing vital new therapies based on a novel peptide platform, today announced that it has raised $5 million in Convertible Note funding, led by Barer & Son Capital with additional funds from Rapha Capital Management, Salem Partners, TEDCO, and Piedmont Capital Partners. In concert with the funding, AsclepiX expanded its board to add Josh Barer, Kevin Slawin, MD, and Sapna Srivastava, PhD, to the founding members Aleksander Popel, PhD and Jordan J. Green, PhD and CEO Wendy Perrow, MBA... (read more)

U.S. FDA Clears Sebacia Microparticles for the Treatment of Mild to Moderate Inflammatory Acne

9/17/2018

 
Picture
Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for its lead product, Sebacia Microparticles. This significant achievement is a milestone in the treatment of acne and follows the company’s completion of its pivotal study, which clearly demonstrated clinical efficacy and safety of Sebacia Microparticles, and its 510(k) submission to the FDA in June 2018... (read more)

Synteract Acquires Dermatology CRO Cu-Tech, LLC

7/11/2018

 
Picture
Synteract has snapped up the specialty contract researcher Cu-Tech, with plans to establish a dedicated center for the development of dermatology products and make the midsized, global CRO into a destination for skin-care clinical trials.
​
The Mountain Lakes, New Jersey-based Cu-Tech has managed more than 130 dermatology trials over the past two decades, covering a variety of indications... (read more)

OncoNano Announces $11.7 Million Series A Financing to Support Development of pH-activated Compound Platform for Disease Detection and Treatment

5/17/2018

 
Picture
SOUTHLAKE, TX - OncoNano Medicine, Inc. today announced the closing of a $11.7 million Series A financing. The transaction was arranged by Salem Partners, who also participated as a principal investor. The Series A funding supplements a $6 million grant previously received from the Cancer Prevention and Research Institute of Texas (CPRIT). The funding will be used to support the company’s continued clinical development of a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease indications such as cancer. The company is also pleased to announce the appointment of five established industry leaders to its Board of Directors... (read more)

Sebacia Announces $36 Million Equity And Debt Financing To Advance Breakthrough In-Office Procedure For Acne

7/25/2017

 
Picture
DULUTH, GA - Sebacia, Inc., a privately held, clinical and commercial stage dermatology and aesthetics company, today announced that the company has completed a $20 million Series D financing led by existing investors Versant Ventures, Domain Associates, Accuitive Medical Ventures and Partners Healthcare Innovation Fund... (read more)

Femasys Announces $40 Million in Series C Financing to Complete Development of FemBloc™

12/15/2016

 
Picture
ATLANTA, GA - Femasys Inc., a developer of innovative medical devices for the women's healthcare market, today announced that it has closed $40 million in Series C financing.  The transaction was arranged by Salem Partners, a Los Angeles-based investment bank which also participated as a principal investor.  The Series C syndicate included multiple... (read more)

Salem partners successfully closes healthcare real estate Joint-Venture

7/27/2016

 
Picture
LOS ANGELES, CA - Salem Partners is pleased to announce the successful completion of a large programmatic joint-venture in the real estate / medical office sector for its client, Everest Medical Core Properties (“Everest MCP”). The joint-venture is between Everest MCP and a major, U.S. based real estate private equity firm.... (read more).

Femasys Announces Todd Creech as Chief Financial Officer

12/14/2015

 
Picture
ATLANTA, GA - December 14, 2015 --- Femasys Inc., a developer of innovative medical devices for the women’s healthcare market today announced the appointment of Todd A. Creech as Chief Financial Officer. Mr. Creech will serve as Femasys’ principal financial and... (read more)

AstraZeneca Agrees to Buy ZS Pharma for $2.7 Billion

11/6/2015

 
Picture
LONDON — The British drug maker AstraZeneca said on Friday that it had agreed to acquire ZS Pharma, a California-based biopharmaceutical company, for $2.7 billion in cash.  The transaction is expected to improve AstraZeneca’s pipeline of treatments for cardiovascular and metabolic diseases and comes as the British drug maker is set to lose exclusivity in the United States for its best-selling cholesterol treatment, Crestor...(read more)

Neos Therapeutics Announces Pricing of Initial Public Offering

7/23/2015

 
Picture
Dallas/Fort Worth, TX (July 23, 2015) — Neos Therapeutics, Inc. (“Neos” or “the Company”) today announced the pricing of its initial public offering of 4,800,000 shares of common stock at an initial public offering price of $15.00 per share. In addition, Neos has granted the underwriters a 30-day option to purchase up to an additional 720,000 shares of common stock at the initial public offering... (read more)

Femasys Secures Term Loan Facility from Silicon Valley Bank 

7/9/2015

 
Picture
ATLANTA, July 9, 2015 /PRNewswire/ -- Femasys Inc., a developer of innovative medical devices for the women's healthcare market, announced today that it has secured a term loan facility from Silicon Valley Bank.  Under the loan facility, the company ... (read more)


Neos Therapeutics files for an IPO with $69 million value

6/23/2015

 
Picture
After bringing in one of the top venture capital investments during first quarter 2015, Neos Therapeutics has filed for an initial public offering.  The Grand Prairie-based company, which develops medication for Attention Deficit/Hyperactivity Disorder, filed Friday to trade on the Nasdaq under ticker symbol NEOS. It has a place holder value... (read more)


<<Previous

    News

    All
    Aerospace & Defense
    Healthcare & Life Sciences
    Industrials
    Investment Banking
    Media & Entertainment
    Real Estate
    Specialty & Lender Finance
    Wealth Management

    Archives

    July 2023
    December 2022
    April 2022
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    February 2021
    December 2020
    August 2020
    November 2019
    August 2019
    July 2019
    December 2018
    November 2018
    September 2018
    July 2018
    June 2018
    May 2018
    April 2018
    January 2018
    November 2017
    July 2017
    February 2017
    December 2016
    November 2016
    October 2016
    July 2016
    December 2015
    November 2015
    October 2015
    July 2015
    June 2015
    May 2015
    April 2015
    December 2014
    October 2014
    August 2014
    July 2014
    June 2014
    April 2014
    March 2014
    November 2013
    October 2013
    February 2013
    December 2012
    October 2012
    February 2012
    January 2012
    December 2011
    September 2011
    August 2011
    June 2011
    January 2010
    December 2009
    November 2009
    August 2009
    June 2009
    February 2009
    September 2008
    August 2008
    July 2008
    June 2008
    May 2008
    April 2008
    February 2008
    December 2007
    July 2007
    May 2007
    February 2007
    January 2007
    December 2006
    November 2006
    October 2006

    RSS Feed

© 2016 by Salem Partners LLC - All Rights Reserved. Member FINRA/SIPC.
11111 Santa Monica Blvd. Suite 2250, Los Angeles, CA 90025
Salem Partners, LLC Form CRS